Parnika Antibiotics Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 18-07-2024
- Paid Up Capital ₹ 0.10 M
as on 18-07-2024
- Company Age 36 Year, 4 Months
- Last Filing with ROC 31 Mar 2023
- Revenue -33.07%
(FY 2022)
- Profit -37.12%
(FY 2022)
- Ebitda 46.13%
(FY 2022)
- Net Worth 10.62%
(FY 2022)
- Total Assets 0.21%
(FY 2022)
About Parnika Antibiotics
The Company is engaged in the Financial Services Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Ashok Damani, Rajkumar Damani, and Sunita Damani serve as directors at the Company.
- CIN/LLPIN
U24230MH1988PTC048379
- Company No.
048379
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
05 Aug 1988
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Parnika Antibiotics?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sunita Damani  | Director | 02-Jun-2021 | Current |
| Ashok Damani | Director | 05-Aug-1988 | Current |
| Rajkumar Damani | Director | 05-Aug-1988 | Current |
Financial Performance and Corporate Structure Insights of Parnika Antibiotics.
Parnika Antibiotics Private Limited, for the financial year ended 2022, experienced significant reduction in revenue, with a 33.07% decrease. The company also saw a substantial fall in profitability, with a 37.12% decrease in profit. The company's net worth Soared by an impressive increase of 10.62%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Parnika Antibiotics?
In 2022, Parnika Antibiotics had a promoter holding of 50.00% and a public holding of 50.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
K. Damani Hospitality Private LimitedActive 19 years 7 monthsAshok Damani and Rajkumar Damani are mutual person
Artha Venture Partners LlpActive 11 years 10 monthsAshok Damani and Sunita Damani are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Parnika Antibiotics?
Unlock and access historical data on people associated with Parnika Antibiotics, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Parnika Antibiotics, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Parnika Antibiotics's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
